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Background
HIV-1 envelope glycoprotein is the primary target for HIV-
1-specific antibodies. The native HIV-1 envelope spike on
the virion surface is a trimer, but trimeric gp140 and mono-
meric gp120 are currently believed to induce comparable
immune responses. Indeed, most studies on the immuno-
genicity of HIV-1 envelope oligomers have revealed only
marginal improvement over monomers. We report here
that stable and homogenous envelope trimers with charac-
teristics expected for the native viral spikes are substantially
superior at eliciting neutralizing antibodies in guinea pigs.
Methods
Stable envelope gp140 trimer derived from clinical isolate
sequences were stabilized with the T4-fibritin C-terminal
trimerization tag and produced in stablely transfected
293T cells. Characterization of Env trimers was performed
by Western blotting, size-exclusion chromatography
(SEC), analytical-ultra centrifugation (AUC), multi-angle
light scattering (MALS) and surface plasmon resonance
(SPR). Guinea pigs were immunized six times with 100 µg
of protein trimer or monomer in CpG/Emulsigen adju-
vants. Antibody responses were determined by ELISA and
TZM.bl neutralizing antibody assays.
Results
Homogeneous trimer and monomer preparations exhib-
ited high purity as measured by SEC and SDS-PAGE.
AUC and MALS analyses revealed expected molecular
weight for both trimer and monomer. SPR analyses
revealed expected binding with CD4 and multiple broadly
neutralizing antibodies. These trimers have markedly dif-
ferent antigenic properties than those of monomeric
gp120s derived from the same sequences. They induce
potent, cross-clade neutralizing antibody responses with
titers substantially higher than those elicited by the corre-
sponding gp120 monomers for a diverse set of both tier 1
and tier 2 viruses.
Conclusion
We have demonstrated the importance of generating high-
quality envelope trimers for antigenic and immunogenic
studies; furthermore these results highlight the immunolo-
gic differences between monomers and high-quality envel-
ope trimers, illustrating important implications for HIV-1
vaccine development and immunogen selection in large
clinical trials.
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